EryDel, a leader in erythrocyte delivery technologies, is specialized in the development of drugs and diagnostics delivered through human red blood cells by using a proprietary fully automated medical device.
Focus on orphan indications.
Lead product, EryDex, for the treatment of Ataxia Telangiectasia (AT), a rare autosomal recessive genetic and neurological disorder for which no established therapy is currently available.
Clinical Proof of Concept achieved (treatment with EryDex met the primary endpoint of improvement in neurological symptoms in a 6-month prospective study in patients with AT).
EryDex was granted the FDA and EMA Orphan Drug Designation for the treatment of AT.
IND obtained and Regulatory path agreed with US FDA.
Erythrocyte Delivery Platform with significant opportunities in other rare diseases (i.e. enzyme replacement) and for diagnostics (i.e. magnetic particle imaging).